Hyperinsulinism‐induced hypoglycemia secondary to asparaginase Erwinia chrysanthemi (recombinant)‐rywn chemotherapy in a pediatric AML patient

Documenti analoghi

• Current surgical practice for central venous access to deliver chemotherapy and enteral access for nutritional support in pediatric patients with an oncological diagnosis
  di: Ceder H. van den Bosch, et al.
  Pubblicazione: (2024)
• Desensitization using pegaspargase in the era of commercially available Erwinia : A single‐institution report on efficacy, cost, and resource utilization
  di: Kira Feldman, et al.
  Pubblicazione: (2024)
• Clinical practice guideline‐inconsistent chemotherapy‐induced vomiting prophylaxis in pediatric cancer patients in community settings: A Children's Oncology Group study
  di: Aaron J. Sugalski, et al.
  Pubblicazione: (2024)
• Palliative care and suicidality: Complicated conversations at two ends of the spectrum
  di: Maryland Pao, et al.
  Pubblicazione: (2024)
• Emergence and Implications of DNMT3A Mutations in Pediatric AML Post‐HSCT: A Case Report and Literature Review
  di: Aarushi Madan, et al.
  Pubblicazione: (2025)